Catalent hires global vp of business development

For Zydis fast-dissolve technology

Catalent Pharma Solutions has appointed Paul Jenkins as Global Vice President Business Development, Zydis Technology. In this role, Jenkins will be responsible for expanding Catalent’s business in fast-dissolve technology across the world. He will be based in Swindon, UK.

Catalent’s proprietary, Zydis fast-dissolve technology has been used in multiple therapeutic segments globally. The firm also recently acquired the development rights to Lyopan fast dissolve technology, which may increase the range of drugs and consumer products that can be used in a fast dissolve dosage form. In addition, Catalent has broad controlled release drug delivery capabilities to help improve therapeutic profiles, patient adherence and bioavailability of treatments.

Prior to joining Catalent, Jenkins was chief executive of Adjuvantix, a UK-based biotechnology company, where he was responsible for all commercial activities and external funding. Prior to that, he was a director of a privately held healthcare consultancy called Ravenhill, where he advised clients on a range of strategic areas in the field of drug delivery, strategy formulation, business development and M&A. Earlier in his career, he worked in increasingly senior business development roles with Phoqus Pharmaceuticals and West Pharmaceutical Services, managing sales and marketing teams across the globe.

You may also like

Manufacturing

Catalent expands integrated development, manufacturing and supply for modalities

Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service
Distribution

Catalent enters commercial supply agreement

Since 2017, Harm Reduction Therapeutics has been working on a low-cost, OTC naloxone product to act as a critical tool to help stem the loss of life
Manufacturing

Catalent expands platform process for viral vectors

Processes can now benefit through increased consistency and efficiency, potentially reducing the time
Manufacturing

Catalent completes $2.2 million expansion to clinical supply facility

The site in Singapore serves the Asia-Pacific region with a wide range of clinical supply services
Drug Delivery

Catalent opens commercial-scale plasmid DNA facility in Belgium

The state-of-the-art facility contains over 12,000 sqft of development and manufacturing space across multiple cleanrooms
Drug Delivery

Catalent to provide supply chain oversight with Case Management Service

It is set to coordinate the scheduling of material collection, the manufacturing slot for the therapy, arrange shipments and continuously manage its status
Research & Development

Developing optimised formulations with minimal drug substance

Advances in in silico and experimental techniques mean that APIs and prototype formulations can be thoroughly characterised using multiple material-sparing assays, allowing the most promising formulation candidates to move on to in vivo studies, reports Lisa Caralli, Science and Technology Director, Pharmaceutics, Catalent
Subscribe now